Specialty Oncology Drugs One of the Top Markets Generating Most Growth

PALM BEACH, Florida, July 31, 2018 /PRNewswire/ --

MarketNewsUpdates.com News Commentary 

Key drivers impacting the market growth of Oncology Drug Candidates are globalization of clinical trials, development of new treatments such as personalized medicine, augmenting evolution in technology and boosting demand to conduct clinical trials. The oncology segment is anticipated to witness the fastest growth. According to various sources, more than USD $38.0 Billion is currently spent by the healthcare industry towards preclinical and clinical development of oncology therapy products. Hence, it is anticipated to grow at a lucrative CAGR and contribute over USD $15.0 Billion towards the clinical trials market by 2025. Advances in new treatments have made cancer a hot investing theme over the past 18 months, helping to power fresh interest in biotechnology stocks. Active companies in the markets today include: Moleculin Biotech, Inc. (NASDAQ:MBRX), OPKO Health, Inc. (NASDAQ:OPK), Celgene Corporation (NASDAQ:CELG), Nektar Therapeutics (NASDAQ:NKTR), BioTime, Inc. (NYSE:BTX).

Moleculin Biotech, Inc. (NASDAQ:MBRX) BREAKING NEWS: Moleculin Biotech, a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced enrollment has opened for a physician-sponsored clinical trial of WP1066 for the treatment of glioblastoma and brain metastases in adults.

"We have been eagerly awaiting the beginning of this physician sponsored clinical trial," commented Walter Klemp, Chairman and CEO of Moleculin. "The trial, which is now listed on clinicaltrials.gov and being conducted at MD Anderson Cancer Center, is now open for enrollment. This is our first investigator initiated trial of WP1066 and an important milestone. Given the unique potential of WP1066, we expect more trials to follow."

The goal of this clinical research study is to find the highest tolerable dose of WP1066 that can be given to patients with recurrent (has returned after treatment) cancerous brain tumors or melanoma that has spread to the brain. The safety of this drug will also be studied.

WP1066 is designed to target the STAT3 pathway in cancer cells, which makes these cells divide, increases new blood vessels to the tumor, causes the cancer cells to move throughout the body and brain, and avoids them being detected by the immune system. We believe that targeting this pathway may cause the immune system to kill the cancer cells. Read this and more news for Moleculin Biotech at: http://www.marketnewsupdates.com/news/mbrx.html